Academic literature on the topic 'Headache Australia'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Headache Australia.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Headache Australia"
1
Martin, Paul R. "Behavioural Approaches to Headaches." Behaviour Change 4, no. 2 (June 1987): 3–5. http://dx.doi.org/10.1017/s0813483900008421.
Full textAbstract:
Headaches are a common problem, and psychological factors are widely acknowledged as playing a critical role in the development and maintenance of a high proportion of cases. This mini series consists of six contributions to the headache literature from researchers working in Australia. The papers focus on cycles in headache activity; behavioural patterns, copying styles and personality characteristics of headache sufferers; psychophysiological pain mechanisms; and potential adverse consequences of simplistic treatment approaches. The emphasis on non-treatment studies is unusual in this field but argued to be appropriate in view of the lack of knowledge concerning basic headache processes.
2
Gregson, Robert A. M. "The Time-Series Analysis of Self-reported Headache Sequences." Behaviour Change 4, no. 2 (June 1987): 6–13. http://dx.doi.org/10.1017/s0813483900008433.
Full textAbstract:
Individual case histories collected variously in Europe and in Australia, recorded over long unbroken sequences, on a daily self-report basis, are potentially analysable as time series. The assessment of spontaneous changes in the dynamics of headache generation and attenuation, and the consequences, if any, of superimposed therapeutic intervention, require that we treat the self-report ratings of headache intensity and duration as a multistate process which is highly autoregressive. Some strong insights into individual differences both in chronic headache patterns, and in response to treatment, are obtained. Of particular interest are individual differences in cyclical and quasi-periodic headaches and in the possible causality of such differences.
3
Silva-Néto, Raimundo Pereira, and Adriana Almeida Soares. "Osmophobia and Odour-triggered Headaches – Review of the Literature and Main Research Centres." European Neurological Review 12, no. 01 (2017): 24. http://dx.doi.org/10.17925/enr.2017.12.01.24.
Full textAbstract:
There is an important relationship between odours and primary headaches. Patients may present osmophobia during headaches and odours may trigger headache attacks. This review aimed to describe the studies on osmophobia, odour-triggered headache, the main researchers and their research centres. Publications on the relationship between odours and primary headaches were searched in 193 sovereign countries and 48 dependent territories in all continents. We consulted the PubMed database and used the descriptors: “osmophobia in [name of the country or territory]”; “odours and headache in [name of the country or territory]” and “smell and headache in [name of the country or territory]”. A total of 254 articles were found, but only 31 articles were considered relevant and composed this review. Of the 31 articles, 90.3% were cross-sectional studies, 6.5% case reports and 3.2% systematic reviews. All studies were performed on three continents: Europe (45.2%), America (32.2%) and Asia (22.6%). For the purpose of this study, North America and South America have been classed as one continent. No research was developed in Africa or Australia. More than 50.0% of the studies were conducted in Italy and Brazil. Only five authors published 38.7% of the studies. Osmophobia during headache attacks was investigated in 67.7% of studies, and odour-triggered headache in 19.3%. Studies on osmophobia and/or odour-triggered headache were carried out in several countries. They were useful in differentiating between migraine and tension-type headache. This could improve the accuracy of diagnosis of migraine compared to the current criteria.
4
Cheng, Shuli, Bronwyn Jenkins, and Elspeth Hutton. "074 Early australian experience with erenumab for chronic migraine." Journal of Neurology, Neurosurgery & Psychiatry 90, e7 (July 2019): A23.2—A23. http://dx.doi.org/10.1136/jnnp-2019-anzan.62.
Full textAbstract:
IntroductionErenumab is available in Australia since October 2018. We review the effectiveness and safety in 2 Australian headache centres.MethodsErenumab (70 mg or 140 mg) was prescribed. We monitored headache days, migraine days, analgesic use, adverse reactions, Headache Impact Test-6 (HIT6) score and Migraine Disability Assessment (MiDAS) score, at baseline and at 3 months. Primary outcomes were reduction in headache and migraine days, and adverse effects. Secondary outcomes were improvement in functional scores and analgesic use.Results65 patients (ages 18–73; mean 44 years) commencing Erenumab were assessed before and after 3 monthly treatments. The duration of chronic migraine (CM) ranged from 1 to 40 years, with 3 to 16 previous failed prophylactic treatments.There was a >50% response in overall headache days and migraine days in 29% (19/65) and 46% (27/59), respectively. There was a modest (10–49%) response in overall headache days and migraine days in 29% (19/65) and 27% (18/59), respectively. There was no improvement in headache days and migraines in 42% (27/65) and 27% (14/59), respectively.At onset, the mean HIT-6 and MiDAS scores were 66 and 65, decreasing after 3 treatments to 59 and 32, respectively. The mean monthly days taking triptan and codeine medications reduced from 9 and 6 days, to 5 and 3 days, respectively.There were few reported side effects.ConclusionThis Australian cohort in tertiary referral refractory migraine patients achieved a significant rate of reduced headache and migraine days with good safety and tolerability.
5
Burke, David. "James Waldo Lance 1926–2019." Historical Records of Australian Science 32, no. 2 (2021): 190. http://dx.doi.org/10.1071/hr21001.
Full textAbstract:
James W. Lance was a clinical neurologist who created the first university-based department of neurology in Australia. He championed academic enquiry and the scientific basis of clinical practice, and his research had two major themes, motor control and headache. After his doctoral studies on the pyramidal tract of the cat, he became a pioneer of the new field of motor control studied in human subjects, making seminal contributions on the control of muscle tone, reflexes and movement in healthy subjects and the pathophysiology of movement disorders in patients. At the same time he developed a clinical research program into the mechanisms and management of headache, in particular migraine. These studies evolved into parallel experiments in human subjects, cats and monkeys, probing the control of the cerebral circulation and the mechanisms underlying craniofacial pain, for which he received international acclaim in both fields. He received international and Australian honours and was the first practising clinician to be elected a fellow of the Australian Academy of Science. He is rightfully credited with leading the development of academic neurology in Australia and overseas.
6
Zhang, Lin, Bronwyn Jenkins, Richard Stark, and Elspeth Hutton. "061 Training in headache in australia, new zealand and asia." Journal of Neurology, Neurosurgery & Psychiatry 90, e7 (July 2019): A20.1—A20. http://dx.doi.org/10.1136/jnnp-2019-anzan.53.
Full textAbstract:
IntroductionMigraine is the leading cause of age-adjusted neurological disability in Australia, but little is known about headache training in our region. We aimed to assess the quantity of teaching in headache subjects during undergraduate and postgraduate years.MethodThis is a cross-sectional survey study where questionnaires were sent to 137 delegates from Australia, New Zealand and Asia, prior to the Headache Master School in Sydney in August 2018. The Main outcome measured are recalled number of hours of teaching in undergraduate year and postgraduate years in: 1) Migraine; 2) Trigeminal autonomic cephalalgias (TACs); 3) Asthma; 4) Myasthenia gravis (MG).ResultsThe questionnaire response rate was 73% (100 of 137), of which 29 delegates were within 10 years of completing their undergraduate degree and 98 were neurologists. In undergraduate training, there was much greater quantity of teaching in asthma than migraine (Z=5.007, p<0.000) despite both being high-prevalent (asthma 11%, migraine 15–20%) conditions. Similarly, for diseases of medium-to-low prevalence, there was less training in TACs (1/1000), compared to MG (1.2/10,000) (Z=6.196, p<0.000). These major differences in training were also seen in postgraduate years even though overall headache teaching was greater in postgraduate than undergraduate training (p<0.000).ConclusionsDespite the high prevalence and morbidity of headache disorders, they receive less attention in training than conditions with similar prevalence. We propose that headache training opportunities should be improved in our region, particularly in the undergraduate course and preceptorships or fellowships in postgraduate years.
7
Wilhelm, Kay, Viola Korczak, Tad Tietze, and Prasuna Reddy. "Clinical pathways for suicidality in emergency settings: a public health priority." Australian Health Review 41, no. 2 (2017): 182. http://dx.doi.org/10.1071/ah16008.
Full textAbstract:
Rates of self-harm in Australia are increasing and constitute a concerning public health issue. Although there are standard treatment pathways for physical complaints, such as headache, abdominal pain and chest pain, in Emergency Medicine, there is no national pathway for self-harm or other psychiatric conditions that present to the emergency department. Herein we outline the difference between clinical practice guidelines and clinical pathways, discuss pathways we have identified on self-harm in Australia and overseas and discuss their applicability to the Australian context and the next steps forward in addressing this public health issue.
8
Grice, I. Darren, Kelly L. Rogers, and Lyn R. Griffiths. "Isolation of Bioactive Compounds That Relate to the Anti-Platelet Activity ofCymbopogon ambiguus." Evidence-Based Complementary and Alternative Medicine 2011 (2011): 1–8. http://dx.doi.org/10.1093/ecam/nep213.
Full textAbstract:
Infusions and decoctions ofCymbopogon ambiguushave been used traditionally in Australia for the treatment of headache, chest infections and muscle cramps. The aim of the present study was to screen and identify bioactive compounds fromC. ambiguusthat could explain this plant’s anti-headache activity. A dichloromethane extract ofC. ambiguuswas identified as having activity in adenosine-diphosphate-induced human platelet aggregation and serotonin-release inhibition bioassays. Subsequent fractionation of this extract led to the isolation of four phenylpropenoids, eugenol, elemicin, eugenol methylether andtrans-isoelemicin. While both eugenol and elemicin exhibited dose-dependent inhibition of ADP-induced human platelet serotonin release, only eugenol displayed potent inhibitory activity with an IC50value of 46.6 μM, in comparison to aspirin, with an IC50value of 46.1 μM. These findings provide evidence to support the therapeutic efficacy ofC. ambiguusin the non-conventional treatment of headache and inflammatory conditions.
9
Benhaddi, Hicham, Sophie McCabe, and Diana T. Lau. "070 Burden of migraine is australia: a systematic literature review." Journal of Neurology, Neurosurgery & Psychiatry 90, e7 (July 2019): A22.2—A22. http://dx.doi.org/10.1136/jnnp-2019-anzan.59.
Full textAbstract:
IntroductionMigraine is a disabling neurological disease characterised by recurrent attacks of moderate to severe headaches. This systematic literature review (SLR) aimed to investigate the clinical, humanistic, and economic burden of chronic migraine (CM), episodic migraine (EM), and of current preventive migraine treatments in Australia.MethodsThe methodology of this SLR was aligned with the National Institute for Health and Care Excellence (NICE) guidelines. An electronic database search was conducted in Embase, MEDLINE and the Cochrane Library, with a time frame of 2008 to 2018.ResultsIn total, 1,122 records were identified and 168 of these were included for data extraction. The prevalence of migraine in Australia is estimated at 18.9%. Of those, 44% of people with EM and 86% of people with CM reported moderate-to-severe disability. Over one-third (36%) of people with EM and nearly two-thirds (64%) of people with CM reported visiting a healthcare provider in the previous three months. No data relating to the economic burden of migraine were returned by the searches. In people with EM and CM, anti-calcitonin gene-related peptide (anti-CGRP) preventive treatments for migraine safely, effectively and significantly reduced the mean number of monthly migraine and/or headache days from baseline compared with placebo.ConclusionsMigraine is associated with a substantial burden, and people living with migraine feel the impact in their day-to-day lives. Anti-CGRPs are a promising class of preventive treatments for all people with migraine. Longer-term studies are needed to determine if the positive effects of anti-CGRPs are sustained over greater time periods.
10
Perry, Jeffrey J., Debra Eagles, Catherine M. Clement, Jamie Brehaut, Anne-Maree Kelly, Suzanne Mason, and Ian G. Stiell. "An international study of emergency physicians' practice for acute headache management and the need for a clinical decision rule." CJEM 11, no. 06 (November 2009): 516–22. http://dx.doi.org/10.1017/s1481803500011775.
Full textAbstract:
ABSTRACTObjective:Patients with acute headache often undergo computed tomography (CT) followed by a lumbar puncture to rule out subarachnoid hemorrhage. Our international study examined current practice, the perceived need for a clinical decision rule for acute headache and the required sensitivity for such a rule.Methods:We approached 2100 emergency physicians from 4 countries (Australia, Canada, the United Kingdom and the United States) to participate in our survey by sampling the membership of their emergency associations. We used a modified Dillman technique with 3–5 notifications and a prenotification letter employing a combination of electronic mail and postal mail. Physicians were questioned about neurologically intact patients who presented with headache. Analysis included both descriptive statistics for the entire sample and stratification by country.Results:The total response rate was 54.7% (1149/2100). Respondents were primarily male (75.5%), with a mean age of 42.5 years and a mean 12.3 years of emergency department (ED) experience. Of the physicians who responded, 49.5% thought all acute headache patients should be investigated with CT and 57.4% felt CT should always be followed by lumbar puncture. Of the respondents, 95.7% reported they would consider using a clinical decision rule for patients with acute headache to rule out subarachnoid hemorrhage. Respondents deemed the median sensitivity required by such a rule to be 99% (interquartile range 98%–99%). Approximately 1 in 5 physicians suggested that 100% sensitivity was required.Conclusion:Emergency physicians report that they would welcome a clinical decision rule for headache that would determine which patients require costly or invasive tests to rule out subarachnoid hemorrhage. The required sensitivity of such a rule was realistic. These results will inform and inspire the development of clinical decision rules for acute headache in the ED.
Books on the topic "Headache Australia"
1
Burdmann, Emmanuel A., and Vivekanad Jha. Rickettsiosis. Edited by Vivekanand Jha. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0193.
Full textAbstract:
Rickettsiae are obligate intracellular bacteria transmitted by arthropods to a vertebrate host. Clinically relevant rickettsioses have a similar clinical pattern, manifesting as an acute febrile disease accompanied by headache, articular and muscle pain, and malaise.Epidemic typhus is a worldwide distributed disease caused by the Rickettsia prowazekii, with a human louse as a vector. Data on epidemic typhus-related renal injury is extremely scarce.Murine typhus is caused by the Rickettsia typhi and has a rodent flea as the vector. It is one of the most frequent rickettsioses, and is usually a self-limited febrile illness. Proteinuria, haematuria, elevations in serum creatinine (SCr) and/or blood urea nitrogen (BUN) and AKI have been reported. The real frequency of renal involvement in murine typhus is unknown. Renal abnormalities recover after the infectious disease resolution.Scrub typhus, caused by the Orientia tsutsugamushi, has the Leptotrombidium mite larva as vector. It is endemic in the Tsutsugamushi triangle delimited by Japan, Australia, India, and Siberia. It can manifest either as a self-limiting disease or as a severe, life-threatening multiorgan illness. Early administration of adequate antibiotics is essential to prevent adverse outcomes. Proteinuria, haematuria, and acute kidney injury (AKI) are frequent.Tick-borne rickettsioses are caused by bacteria from the spotted fever group and have ticks as vectors. Rocky Mountain spotted fever (RMSF) is caused by Rickettsia rickettsii. It is the most severe of the spotted fever rickettsial diseases, causing significant morbidity and lethality. RMSF occurs in North, Central, and South America. Renal impairment is frequent in severe forms of RMSF. Mediterranean spotted fever is caused by Rickettsia conorii, and is endemic in the Mediterranean area. It is usually a benign disease, but may have a severe course, clinically similar to RMSF. Haematuria, proteinuria, increased serum creatinine, and AKI may occur. Japanese spotted fever is caused by Rickettsia japonica. Lethal cases are reported yearly and AKI has occurred in the context of multiple organ failure.
Book chapters on the topic "Headache Australia"
1
Wallace, Daniel J., and Janice Brock Wallace. "How Our Understanding of Fibromyalgia Evolved." In All About Fibromyalgia. Oxford University Press, 2002. http://dx.doi.org/10.1093/oso/9780195147537.003.0006.
Full textAbstract:
There are times when rheumatologists have been accused of making up new syndromes. For example, in the last 20 years, our specialty has described new rheumatic entities including Lyme disease, the musculoskeletal manifestations of acquired immune deficiency syndrome (AIDS), eosinophilic myalgia syndrome (from L-tryptophan contamination), and siliconosis (which, if it exists, results from silicone breast implants). Fibromyalgia is not in this group. Evidence for the syndrome can be found as far back in history as the book of Job, where he complained of “sinews (that) take no rest.” Seemingly exaggerated tenderness of the muscles and soft tissues to touch was documented in the nineteenth-century medical literature by French, German, and British scientists, who called it spinal irritation, Charcot’s hysteria, or a morbid affection. Tender points were first described by Balfour in 1824 and Villieux in 1841. The English physician Sir William R. Gowers (1845-1915) coined the term fibrositis in 1904 in a paper on lumbago (low back pain) when he tried to describe inflammatory changes in the fibrous tissues of the muscles of the low back. Gowers was wrong. There is no such thing as inflammation of the fibrous tissues, but the term lived on because British physicians used fibrositis to denote pain in the upper back and neck areas among Welsh coal miners in the 1920s and 1930s. The definition of fibrositis cross-pollinated during the Second World War when United States, Canadian, Australian, and New Zealand physicians served with their British counterparts. Soldiers who were unwilling to fight or who experienced shell shock, or complained of aches and pains due to carrying heavy gear without any obvious disease, were diagnosed as having fibrositis. A symptom complex of fatigue, palpitations, dizziness, gastrointestinal symptoms, headache, sleep disturbance, and aching was first noted by the Union physician J. M. da Costa among 300 soldiers during the Civil War who had what he termed an “irritable heart.” The first mention of fibrositis in the North American medical literature appeared in a rheumatology textbook chapter written by Wallace Graham in 1940.
Reports on the topic "Headache Australia"
1
Alhusuny, Ameer, Margaret Cook, Akram Khalil, and Venerina Johnston. Neck/Shoulder Problems and Headaches Among Surgeons Performing Minimally Invasive Surgeries in Australia and New Zealand. Peeref, July 2022. http://dx.doi.org/10.54985/peeref.2207p9199360.
Full text